F
Foghorn Therapeutics
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,
About Foghorn Therapeutics
Foghorn Therapeutics was founded by Adrian Gottschalk, Gerald Crabtree, and Cigall Kadoch, driven by a shared vision to revolutionize the treatment of complex diseases through gene expression modulation. The company's inception was rooted in groundbreaking research from Stanford University, where Crabtree and Kadoch explored the intricacies of chromatin regulation.
Read full description
In October 2020, Foghorn Therapeutics made a significant leap by going public on the NASDAQ under the ticker FHTX, raising $120 million. This IPO marked a pivotal moment, providing the company with the capital to advance its innovative platform and pipeline of precision medicines targeting genetic dependencies.
Foghorn's approach focuses on correcting abnormal gene expression, a method that holds promise for treating a range of diseases, including cancer. By leveraging their proprietary Gene Traffic Control platform, the company aims to develop therapies that can precisely target and modulate the chromatin regulatory system.
As Foghorn Therapeutics continues to grow, it remains committed to its mission of transforming patient care through scientific innovation. The company's journey reflects a blend of academic excellence and entrepreneurial spirit, positioning it as a leader in the field of gene therapy.
At a glance
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Latest news
Press, funding announcements and product moves mentioning Foghorn Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Flagship Pioneering
BVF Partners
Deerfield
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Foghorn Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Foghorn Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.